The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...

Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Congress and the Florida Legislature must eliminate cost disparities between opioid and non-opioid options.

The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the ...

If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...

To read more letters to the editor, go to oregonlive.com/opinion.

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Latigo Biotherapeutics CEO Nima Farzan stated: “The need for non-opioid pain treatments has never been more urgent, and this financing allows us to accelerate the development of our robust ...

Ark is already conducting studies with this new class of pain medication, leveraging its strong infrastructure, experienced staff, and extensive access to patient populations. With strong community ...